Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKRO NASDAQ:REGN NASDAQ:VRTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKROAkero Therapeutics$53.72+0.2%$47.89$21.34▼$58.40$4.29B-0.294.02 million shs1.60 million shsREGNRegeneron Pharmaceuticals$575.69-1.5%$576.37$476.49▼$952.02$61.97B0.311.08 million shs778,752 shsVRTXVertex Pharmaceuticals$422.63-0.9%$398.38$362.50▼$519.88$109.34B0.431.50 million shs1.76 million shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKROAkero Therapeutics+0.21%+0.11%+12.29%+6.25%+87.37%REGNRegeneron Pharmaceuticals-1.55%+1.15%+1.37%+2.24%-38.85%VRTXVertex Pharmaceuticals-0.89%+3.43%+11.30%-10.01%-10.09%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKROAkero Therapeutics$53.72+0.2%$47.89$21.34▼$58.40$4.29B-0.294.02 million shs1.60 million shsREGNRegeneron Pharmaceuticals$575.69-1.5%$576.37$476.49▼$952.02$61.97B0.311.08 million shs778,752 shsVRTXVertex Pharmaceuticals$422.63-0.9%$398.38$362.50▼$519.88$109.34B0.431.50 million shs1.76 million shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKROAkero Therapeutics+0.21%+0.11%+12.29%+6.25%+87.37%REGNRegeneron Pharmaceuticals-1.55%+1.15%+1.37%+2.24%-38.85%VRTXVertex Pharmaceuticals-0.89%+3.43%+11.30%-10.01%-10.09%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKROAkero Therapeutics 2.31Hold$73.3836.59% UpsideREGNRegeneron Pharmaceuticals 2.79Moderate Buy$802.3539.37% UpsideVRTXVertex Pharmaceuticals 2.62Moderate Buy$494.3816.98% UpsideCurrent Analyst Ratings BreakdownLatest AKRO, REGN, and VRTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/23/2025REGNRegeneron PharmaceuticalsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$850.0010/14/2025REGNRegeneron PharmaceuticalsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$850.0010/13/2025REGNRegeneron PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$650.00 ➝ $660.0010/10/2025VRTXVertex PharmaceuticalsMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetEqual Weight$439.00 ➝ $438.0010/10/2025AKROAkero TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$72.00 ➝ $54.0010/10/2025AKROAkero TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold10/10/2025AKROAkero TherapeuticsTD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold10/10/2025AKROAkero TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$72.00 ➝ $54.0010/10/2025AKROAkero TherapeuticsWolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Hold10/10/2025REGNRegeneron PharmaceuticalsMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$761.00 ➝ $756.0010/9/2025AKROAkero TherapeuticsLifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold(Data available from 10/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKROAkero TherapeuticsN/AN/AN/AN/A$10.75 per shareN/AREGNRegeneron Pharmaceuticals$14.21B4.29$44.98 per share12.80$268.50 per share2.14VRTXVertex Pharmaceuticals$11.02B9.83N/AN/A$63.72 per share6.63Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKROAkero Therapeutics-$252.06M-$2.00N/AN/AN/AN/A-15.84%-14.59%11/14/2025 (Estimated)REGNRegeneron Pharmaceuticals$4.41B$39.6814.5115.141.8231.37%15.06%11.77%10/28/2025 (Estimated)VRTXVertex Pharmaceuticals-$535.60M$13.9930.2124.14N/A31.86%23.91%17.14%11/3/2025 (Estimated)Latest AKRO, REGN, and VRTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/14/2025Q3 2025AKROAkero Therapeutics-$0.94N/AN/AN/AN/AN/A11/3/2025Q3 2025VRTXVertex Pharmaceuticals$4.56N/AN/AN/A$3.05 billionN/A10/28/2025Q3 2025REGNRegeneron Pharmaceuticals$9.73N/AN/AN/A$3.57 billionN/A8/8/2025Q2 2025AKROAkero Therapeutics-$0.97-$0.86+$0.11-$0.86N/AN/A8/4/2025Q2 2025VRTXVertex Pharmaceuticals$4.24$4.52+$0.28$3.99$2.90 billion$2.94 billion8/1/2025Q2 2025REGNRegeneron Pharmaceuticals$8.43$12.89+$4.46$12.81$3.30 billion$3.68 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKROAkero TherapeuticsN/AN/AN/AN/AN/AREGNRegeneron Pharmaceuticals$3.520.61%N/A8.87%N/AVRTXVertex PharmaceuticalsN/AN/AN/AN/AN/ALatest AKRO, REGN, and VRTX DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date8/1/2025REGNRegeneron Pharmaceuticalsquarterly$0.880.6%8/18/20258/18/20259/3/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKROAkero Therapeutics0.0212.6612.66REGNRegeneron Pharmaceuticals0.094.603.72VRTXVertex PharmaceuticalsN/A2.522.16Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKROAkero TherapeuticsN/AREGNRegeneron Pharmaceuticals83.31%VRTXVertex Pharmaceuticals90.96%Insider OwnershipCompanyInsider OwnershipAKROAkero Therapeutics7.07%REGNRegeneron Pharmaceuticals7.02%VRTXVertex Pharmaceuticals0.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKROAkero Therapeutics3079.99 million74.33 millionOptionableREGNRegeneron Pharmaceuticals15,106105.99 million98.55 millionOptionableVRTXVertex Pharmaceuticals6,100256.39 million255.88 millionOptionableAKRO, REGN, and VRTX HeadlinesRecent News About These CompaniesVertex Pharmaceuticals Incorporated $VRTX Position Boosted by Smith Group Asset Management LLC1 hour ago | marketbeat.comBleakley Financial Group LLC Has $6.20 Million Position in Vertex Pharmaceuticals Incorporated $VRTX2 hours ago | marketbeat.comVertex Pharmaceuticals Incorporated: Vertex Presents New Data Across Portfolio of Cystic Fibrosis Medicines Including ALYFTREK at the North American Cystic Fibrosis ConferenceOctober 23 at 12:07 PM | finanznachrichten.deBank of America Securities Remains Bullish on Vertex Pharmaceuticals Incorporated (VRTX)October 22 at 12:30 AM | insidermonkey.comVertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on ItOctober 22 at 10:00 AM | zacks.comARK Investment Management LLC Sells 2,281 Shares of Vertex Pharmaceuticals Incorporated $VRTXOctober 22 at 9:13 AM | marketbeat.com2,440 Shares in Vertex Pharmaceuticals Incorporated $VRTX Acquired by Phoenix Financial Ltd.October 22 at 6:01 AM | marketbeat.comVertex Pharmaceuticals price target lowered to $563 from $565 at BofAOctober 21 at 2:59 PM | msn.comHealthcare's Shift to Prevention Gains Momentum as Markets Reach Critical MassOctober 21 at 9:58 AM | baystreet.caVertex Pharmaceuticals’ Promising Kidney Franchise: Andrew Fein’s Buy Rating on Innovative Povetacicept and Strategic ExpansionOctober 21 at 8:10 AM | tipranks.comVertex Pharmaceuticals: Strong Market Position and Growth Potential Reinforce Buy RatingOctober 21 at 6:51 AM | tipranks.comDekaBank Deutsche Girozentrale Boosts Stock Position in Vertex Pharmaceuticals Incorporated $VRTXOctober 21 at 5:28 AM | marketbeat.comVertex Pharmaceuticals Incorporated $VRTX Shares Sold by William Blair Investment Management LLCOctober 21 at 4:27 AM | marketbeat.comStratos Wealth Partners LTD. Sells 1,083 Shares of Vertex Pharmaceuticals Incorporated $VRTXOctober 21 at 4:17 AM | marketbeat.comBogart Wealth LLC Purchases 6,240 Shares of Vertex Pharmaceuticals Incorporated $VRTXOctober 20, 2025 | marketbeat.comNordea Investment Management AB Has $10.89 Million Holdings in Vertex Pharmaceuticals Incorporated $VRTXOctober 20, 2025 | marketbeat.comMutual of America Capital Management LLC Sells 2,069 Shares of Vertex Pharmaceuticals Incorporated $VRTXOctober 19, 2025 | marketbeat.comCwm LLC Sells 776 Shares of Vertex Pharmaceuticals Incorporated $VRTXOctober 18, 2025 | marketbeat.comVertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney WeekOctober 17, 2025 | businesswire.comChevy Chase Trust Holdings LLC Sells 2,121 Shares of Vertex Pharmaceuticals Incorporated $VRTXOctober 17, 2025 | marketbeat.comTweedy Browne Co LLC Sells 1,063 Shares of Vertex Pharmaceuticals Incorporated $VRTXOctober 17, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAKRO, REGN, and VRTX Company DescriptionsAkero Therapeutics NASDAQ:AKRO$53.72 +0.11 (+0.21%) Closing price 10/23/2025 04:00 PM EasternExtended Trading$53.62 -0.09 (-0.18%) As of 10/23/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.Regeneron Pharmaceuticals NASDAQ:REGN$575.69 -9.05 (-1.55%) Closing price 10/23/2025 04:00 PM EasternExtended Trading$575.72 +0.03 (+0.01%) As of 07:51 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.Vertex Pharmaceuticals NASDAQ:VRTX$422.63 -3.81 (-0.89%) Closing price 10/23/2025 04:00 PM EasternExtended Trading$423.45 +0.82 (+0.19%) As of 07:52 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tesla’s Earnings Review: Does the Juice Justify the Squeeze? Warner Bros. Bidding War Potential: How High Could WBD Shares Go? Boeing Takes Off as FAA Greenlights 737 MAX Production Boost Capital One Just Flashed a Buy Signal—New Highs Could Be Next Why Intuitive Surgical Is a No-Brainer for Long-Term Investors Is Oracle’s AI Rally Over? Wall Street Thinks ORCL Could Hit $400 GM Posts Largest Gain Since the Pandemic: Shares Still Look Cheap 3 Pharmaceutical Growth Stocks to Buy and Hold for 10 Years Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
